{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:54:43Z","timestamp":1787007283872,"version":"build-2736575974"},"reference-count":48,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14737140.2025.2587296","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T23:22:31Z","timestamp":1762816951000},"page":"333-344","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["The role of gemcitabine\u2013docetaxel in the management of NMIBC: a scoping review of current status and future directions"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-4325","authenticated-orcid":false,"given":"Kevin G.","family":"Keane","sequence":"first","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Redfern","sequence":"additional","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Lim","sequence":"additional","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickon","family":"Hayne","sequence":"additional","affiliation":[{"name":"University of Western Australia","place":["Perth, Australia"]},{"name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","place":["Camperdown, Australia"]},{"name":"South Metropolitan Health Service","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.07.014"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4504"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.068"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.031"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1399"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0242"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1422"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14423"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002740"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003977"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849"},{"issue":"1","key":"e_1_3_5_18_1","first-page":"e9.1","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG [comparative study research support, non-U.S. Gov\u2019t]","volume":"40","author":"Steinberg RL","year":"2022","unstructured":"Steinberg RL, Packiam VT, Thomas LJ, et al. Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG [comparative study research support, non-U.S. Gov\u2019t]. Urol. 2022;40(1):.e9.1\u2013.e9.7.","journal-title":"Urol"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16645"},{"key":"e_1_3_5_20_1","first-page":"17","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer","volume":"17","author":"Taylor J","year":"2024","unstructured":"Taylor J, Kamat AM, Annapureddy D, et al. Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. Eur Urol Oncol. 2024;17:17.","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"e_1_3_5_21_1","first-page":"e458.1","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim K","year":"2023","unstructured":"Yim K, Melnick K, Mott SL, et al. Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol. 2023;41(11):.e458.1\u2013.e458.7.","journal-title":"Urol"},{"issue":"12","key":"e_1_3_5_22_1","first-page":"e485.1","article-title":"Sequential intravesical gemcitabine and docetaxel for treatment-naive and previously treated intermediate-risk nonmuscle invasive bladder cancer","volume":"41","author":"McElree IM","year":"2023","unstructured":"McElree IM, Orzel J, Stubbee R, et al. Sequential intravesical gemcitabine and docetaxel for treatment-naive and previously treated intermediate-risk nonmuscle invasive bladder cancer. Urol. 2023;41(12):.e485.1\u2013.e485.7.","journal-title":"Urol"},{"key":"e_1_3_5_23_1","first-page":"20","article-title":"Comparative effectiveness of bacillus Calmette-Guerin and sequential intravesical gemcitabine and docetaxel for treatment-naive intermediate-risk non-muscle-invasive bladder cancer","volume":"20","author":"Kolanukuduru KP","year":"2024","unstructured":"Kolanukuduru KP, Ben-David R, Lidagoster S, et al. Comparative effectiveness of bacillus Calmette-Guerin and sequential intravesical gemcitabine and docetaxel for treatment-naive intermediate-risk non-muscle-invasive bladder cancer. Eur Urol Focus. 2024;20:20.","journal-title":"Eur Urol Focus"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS897"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244125"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524098"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14070789"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.214"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05613-5"},{"issue":"3","key":"e_1_3_5_30_1","first-page":"e148.1","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer [Research Support, N.I.H. Extramural Research Support, Non-U.S. Gov\u2019t]","volume":"41","author":"Chevuru PT","year":"2023","unstructured":"Chevuru PT, McElree IM, Mott SL, et al. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer [Research Support, N.I.H. Extramural Research Support, Non-U.S. Gov\u2019t]. Urol. 2023;41(3):.e148.1\u2013.e148.7.","journal-title":"Urol"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"issue":"2","key":"e_1_3_5_32_1","first-page":"e40.17","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels MJ","year":"2020","unstructured":"Daniels MJ, Barry E, Milbar N, et al. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer. Urol. 2020;38(2):.e40.17\u2013.e40.24.","journal-title":"Urol"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.06.006"},{"key":"e_1_3_5_34_1","unstructured":"A randomized phase III trial of intravesical BCG versus intravesical docetaxel and gemcitabine treatment in BCG na\u00efve high grade non-muscle invasive bladder cancer (BRIDGE) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05538663"},{"key":"e_1_3_5_35_1","unstructured":"Combination chemotherapy versus bacillus Calmette-Gu\u00e9rin (BCG) for high-risk non-muscle invasive bladder cancer a phase III multi-centre randomised controlled trial (COBRA). Available from: https:\/\/www.fundingawards.nihr.ac.uk\/award\/NIHR160459?utm_source=chatgpt.com"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.001"},{"key":"e_1_3_5_37_1","unstructured":"MC240502 In-home intravesical therapy (invite) study - a phase Ib\/II single-arm trial of delivering intravesical therapy for bladder cancer in patients\u2019 homes. [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06704191"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-190245"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003195"},{"key":"e_1_3_5_40_1","unstructured":"Klaassen Z. Prospective open label study to evaluate the safety and efficacy of intravesical sustained release gemcitabine docetaxel combination (NDV-01) in high. Risk (NM)IBC: UroToday; 2025. Available from: https:\/\/www.urotoday.com\/conference-highlights\/aua-2025\/aua-2025-bladder-cancer\/160107-aua-2025-prospective-open-label-study-to-evaluate-the-safety-and-efficacy-of-intravesical-sustained-release-gemcitabine-docetaxel-combination-ndv-01-in-high-risk-nmibc.html?utm_source=chatgpt.com"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.667"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.703"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS891"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.832"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1039\/D4BM01471E"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16486"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217339"},{"key":"e_1_3_5_48_1","unstructured":"Guidance of adjuvant instillation in intermediate risk non-muscle invasive bladder cancer by drug screens in patient derived organoids. A single center open-label phase II trial with a feasibility endpoint. (GAIN-Inst-Trial). [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05024734"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16332"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.70012"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2587296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:46:07Z","timestamp":1772765167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2587296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14737140.2025.2587296"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2587296","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}